



February 6, 2026

To,
The Corporate Relations Department
The BSE Limited
Department of Corporate Services
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001.
Ref:- Scrip Code:- 500126

To,
The Listing Department
The National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (East),
Mumbai – 400051
Ref:- Symbol:- PGHL

Dear Sir / Madam,

Sub: Press release on unaudited Financial Results for the quarter ended December 31, 2025

We are enclosing herewith the Press Release, regarding the unaudited Financial Results for quarter ended December 31, 2025, approved at a meeting of the Board of Directors of the Company held today.

Kindly take the same on record.

Thanking you.
Yours faithfully,

For **Procter & Gamble Health Limited**

Zeal Rupani
Company Secretary



Procter & Gamble Health Announces Third Quarter Results

Sales up 21% for the quarter ended December 31, 2025

Mumbai, February 6, 2026: Procter & Gamble Health Ltd. (PGHL) today announced its financial results for the third quarter ended December 31, 2025. The Company delivered sales of ₹368 crores, up 21% versus a year ago, driven by strong brand fundamentals and positive consumer response to new innovations. Profit After Tax (PAT) stood at ₹78 crores for the quarter.

Mr. Milind Thatte, Managing Director, P&G Health, said, "We delivered a strong top-line growth in the quarter, continuing the momentum from the first half of the financial year. This comes behind our strategic efforts across the value chain, including new innovations like Livogen Iron Gummies and Neurobion Nerve Pain Relief Cream, and strengthening of supply chain capabilities. We remain committed towards addressing the evolving needs of our consumers, customers and healthcare professionals, via superior brand building, go to market initiatives, and innovations backed by science to help our consumers live healthier and more vibrant lives.

We are delivering sustainable, balanced growth and value creation for all our stakeholders, driven by our strategy that is centred on a focused portfolio of quality, trusted, and highly recommended brands where performance drives brand choice; superiority (across product, package, brand communication, retail execution and value), constructive disruption and an agile accountable organization."

The Company has declared an interim dividend of ₹160 per equity share (including one-time special dividend of ₹50 per share) for the financial year 2025-26.

About Procter & Gamble Health Limited: Procter & Gamble Health Limited is one of India's largest vitamins, minerals, and supplements (VMS) companies manufacturing and marketing VMS products for a healthy lifestyle and improved quality of life, including Neurobion, Livogen, SevenSeas, Evion, Polybion and Nasivion. Please visit www.pghealthindia.com for the latest news and information about Procter & Gamble Health Limited and its brands.

About Procter & Gamble: P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Ambi Pur®, Ariel®, Gillette®, Braun®, Head & Shoulders®, Olay®, Oral-B®, Pampers®, Pantene®, Herbal Essences®, Tide®, Vicks®, Old Spice® and Whisper®. P&G operates in approximately 70 countries worldwide.

CONTACTS

Media Contacts - Procter & Gamble Health Limited:

Vishesh Bohre | bohre.v@pg.com

Agency Contact – SPAG FINN Partners

Sarah Rajan | sarah.rajan@finnpartners.com

Desiree Crasto | desiree.crasto@finnpartners.com

Procter & Gamble Health Limited

CIN: L99999MH1967PLC013726

Registered Office: Ground Floor and First Floor,
P&G Plaza, Cardinal Gracias Road, Chakala,
Andheri-E, Mumbai-400 099 | Tel: (91-22) 6866 9000
www.pghealthindia.com